• Juan José Tejada-Pérez, Juan José Vázquez-Vicente, María Renée Herrera-Burgos, Francisco Gabriel Martín-Martín, Tesifón Parrón-Carreño, and Raquel Alarcón-Rodríguez.
• Faculty of Health Sciences, University of Almería, Carr. Sacramento, s/n, 04120 La Cañada, Almeria, Spain.
• Vaccines (Basel). 2021 Mar 19; 9 (3).

AbstractHepatitis B (HBV) is a pathogen virus with transmission mechanisms that include contact with the infected blood or bodily fluids of the infected organism. Nowadays, healthcare workers are one of the most exposed groups to HBV. Conventionally, completing a vaccine series dosage with Engerix B® lowers this risk by providing workers with immunity to the virus. However, through the years, we have encountered nonresponsive health personnel to the Engerix B® vaccine; hence, the Occupational Health Service of Poniente Hospital studied the Fendrix® adjuvanted vaccine as an alternative vaccine to develop immunological responses in healthcare workers who do not respond to vaccination with Engerix B®. In our study, we employed a vaccination schedule with the Fendrix® vaccine, performing serology tests on the cases after the application of each dose. The results obtained showed humoral immunity in 92.3% of the cases, with a remarkable increase in antibody titer after the first doses. These encouraging results support the future inclusion of this vaccine as one possible alternative for the immunization to HBV for healthcare workers nonresponsive to Engerix B®.

4 keywords...

hide…